ClinicalTrials.gg
CompletedNCT01566162Updated Apr 9, 2019Results posted

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

A Phase 3 interventional study of Lurasidone in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 63 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-09.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
191
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
17th of 39
191 · median 149
Started
2012
with 4 others
Phase 3
18 of 39
none open now
Registered
19th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 17th largest by enrollment, is one of 5 that started in 2012, is one of 18 in phase 3, and was the 19th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.

Read the detailed description

This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia who have participated in Study D1050238, a double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia. Subjects who have completed the 28-week double-blind phase or who have experienced a protocol-defined relapse event during the double-blind phase of study D1050238 will have the option to participate in this study. In addition, if/when the study is discontinued by the sponsor, all subjects participating in the open-label phase and the double-blind phase of study D1050238 will have the option to participate in this extension study

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Lurasidone
  • Latuda
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has agreed to participate by providing written .
  • Subject will be eligible to participate if one of the following criteria is met:
  • Subject has completed the 28-week double-blind phase of study D1050238
  • Subject has experienced a protocol-defined relapse event during the double- blind phase in study D1050238
  • Subject is participating in the open-label or double-blind phase of study D1050238 if/when study D1050238 is terminated by the sponsor.
  • Subject has completed all required assessments on the final study visit (Study Visit Number 42) in study D1050238.
  • Subject is judged by the Investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
  • Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at the extension baseline visit (Study Visit Number 42 in study D1050238). Subjects who answer "yes" to this question must be referred by the Investigator for appropriate follow-up evaluation and treatment.
  • Subject tests positive for drugs of abuse or is suspected of current alcohol abuse at the extension baseline visit (Study Visit Number 42 in study D1050238). In the event a subject tests positive for cannabinoids, the Investigator will evaluate the subject's ability to abstain from cannabis during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Lurasidone

    Lurasidone 40 - 80mg flexible dose

    Drug: Lurasidone

Interventions

  • Lurasidone 40-80 mg taken orally taken once daily

06

What researchers measure

Primary outcomes

  1. Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs)

    Number of subjects with treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, and serious AEs (SAEs)

    Time frame: 12 weeks

  2. Efficacy - Change in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: Baseline to week 12 LOCF endpoint

  3. Efficacy - Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score.

    The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

    Time frame: Baseline to week 12 LOCF endpoint

Secondary outcomes

  1. Change From Baseline in Montgomery -Asberg Depression Rating Scale Total Score

    The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

    Time frame: Baseline to week 12 LOCF endpoint

  2. Short Form-12 Health Survey (SF-12)

    The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales. Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

    Time frame: Baseline to week 12 LOCF endpoint

  3. Modified Specific Levels of Functioning (SLOF) Total Score.

    The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items, each item is rated on a 5-point scale and mapped to 0 to 4. The total score will be the sum of all 24 items and ranges from 0 to 96. A higher score indicates worse condition.

    Time frame: 12 weeks

  4. Brief Adherence Rating Scale (BARS)

    The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 100%) of doses taken by the subject in the previous month.

    Time frame: 12 weeks

  5. Smoking Questionnaire

    Smoking questionnaire - average number of cigarettes per day at week 12 (LOCF).

    Time frame: 12 weeks

  6. Intent to Attend Assessment

    The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the baseline visit: "How likely is it that you will complete the study?"

    Time frame: 12 weeks

07

Results

Posted Nov 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneLurasidone
Started191
Completed155
Not completed36

Outcome measures

PrimarySafety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs)

Number of subjects with treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, and serious AEs (SAEs)

Time frame:
12 weeks
Reported as:
Number · participants
Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs)
participantsLurasidone
Subjects with TEAEs72
TEASs leading to discontinuation7
Subjects with TESAEs13
PrimaryEfficacy - Change in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
Baseline to week 12 LOCF endpoint
Reported as:
Mean · units on a scale
Efficacy - Change in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleLurasidone
Efficacy - Change in Positive and Negative Syndrome Scale (PANSS) Total Score-8.4 ± 15.06
PrimaryEfficacy - Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score.

The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

Time frame:
Baseline to week 12 LOCF endpoint
Reported as:
Mean · units on a scale
Efficacy - Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score.
units on a scaleLurasidone
Efficacy - Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score.-0.48 ± 1.051
SecondaryChange From Baseline in Montgomery -Asberg Depression Rating Scale Total Score

The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

Time frame:
Baseline to week 12 LOCF endpoint
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery -Asberg Depression Rating Scale Total Score
units on a scaleLurasidone
Change From Baseline in Montgomery -Asberg Depression Rating Scale Total Score-3.3 ± 7.83
SecondaryShort Form-12 Health Survey (SF-12)

The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales. Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

Time frame:
Baseline to week 12 LOCF endpoint
Reported as:
Mean · units on a scale
Short Form-12 Health Survey (SF-12)
units on a scaleLurasidone
Short Form-12 Health Survey (SF-12)-0.45 ± 6.642
SecondaryModified Specific Levels of Functioning (SLOF) Total Score.

The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items, each item is rated on a 5-point scale and mapped to 0 to 4. The total score will be the sum of all 24 items and ranges from 0 to 96. A higher score indicates worse condition.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Modified Specific Levels of Functioning (SLOF) Total Score.
units on a scaleLurasidone
Modified Specific Levels of Functioning (SLOF) Total Score.-1.8 ± 9.55
SecondaryBrief Adherence Rating Scale (BARS)

The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 100%) of doses taken by the subject in the previous month.

Time frame:
12 weeks
Reported as:
Mean · percentage of monthly doses taken
Brief Adherence Rating Scale (BARS)
percentage of monthly doses takenLurasidone
Brief Adherence Rating Scale (BARS)99.0 ± 3.08
SecondarySmoking Questionnaire

Smoking questionnaire - average number of cigarettes per day at week 12 (LOCF).

Time frame:
12 weeks
Reported as:
Mean · number of cigarettes smoked daily
Smoking Questionnaire
number of cigarettes smoked dailyLurasidone
Smoking Questionnaire11.1 ± 9.95
SecondaryIntent to Attend Assessment

The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the baseline visit: "How likely is it that you will complete the study?"

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Intent to Attend Assessment
units on a scaleLurasidone
Intent to Attend Assessment8.3 ± 1.14

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone—13/191 (6.8%)34/191 (17.8%)
Most frequent serious events
Most frequent serious events
EventLurasidone
SchizophreniaPsychiatric disorders6/191
Psychotic DisorderPsychiatric disorders4/191
Artrial flutterCardiac disorders1/191
Chest PainGeneral disorders1/191
PneumoniaInfections and infestations1/191
HypotensionVascular disorders1/191
Most frequent other events
Most frequent other events
EventLurasidone
AkathisiaNervous system disorders10/191
SchizophreniaPsychiatric disorders8/191
NasopharyngitisInfections and infestations5/191
DiarrhoeaGastrointestinal disorders4/191
NauseaGastrointestinal disorders4/191
HeadacheNervous system disorders4/191
AnxietyPsychiatric disorders4/191
InsomniaPsychiatric disorders4/191

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lurasidone
Mean42.7 ± 12.30
Age, Categorical
Age, Categorical(Participants)Lurasidone
<=18 years0
Between 18 and 65 years190
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone
Female76
Male115
Region of Enrollment
Region of Enrollment(participants)Lurasidone
Serbia22
France4
United States114
Slovakia15
Russia19
South Africa17
08

Study locations

63 sites
  • K and S Professional Research Services
    Little Rock, Arkansas 72201, United States
  • Woodland International Research Inc.
    Little Rock, Arkansas 72211, United States
  • Comprehensive Clinical Development Inc.
    Cerritos, California 90703, United States
  • Diligent Clinical Trials
    Downey, California 90241, United States
  • Synergy Clinical Research Center
    Escondido, California 92025, United States
  • CNS Network
    Garden Grove, California 92845, United States
  • AXIS Clinical Trials
    Los Angeles, California 90036, United States
  • Synergy Clinical Research Center
    National City, California 91950, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • CNRI-Los Angeles. LLC
    Pico Rivera, California 90660, United States
  • California Neuropsychopharmacolgoy Clinical Research Insitute
    San Diego, California 92126, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • Collaborative Neuroscience Network
    Torrance, California 90502, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • Accurate Clinical Trials
    Kissimmee, Florida 34742, United States
  • Galiz Research
    Miami Springs, Florida 33166, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Comprehensive NeuroScience Inc.
    Atlanta, Georgia 30328, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70601, United States
  • Lousiana Clinical Research, LLC
    Shreveport, Louisiana 71104, United States
  • Center for Behavioral Health, LLC
    Rockville, Maryland 20850, United States
  • Psychiatric Care and Research Center
    O'Fallon, Missouri 63368, United States
  • Psych Care Consultants Research
    Saint Louis, Missouri 63128, United States
  • Robert Lynn Horne, MD
    Las Vegas, Nevada 89102, United States
  • CRI Worldwide LLC
    Willingboro, New Jersey 08046, United States
  • Erie County Medical Center, Corp
    Buffalo, New York 14215, United States
  • Neurobehavioral Research Inc.
    Cedarhurst, New York 11516, United States
  • Comprehensive Clinical Development, Inc
    Fresh Meadows, New York 11366, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Oklahoma Clinical Research
    Oklahoma City, Oklahoma 73116, United States
  • CRI Worldwide LLC at Kirkbride
    Philadelphia, Pennsylvania 19139, United States
  • Lincoln Research
    Lincoln, Rhode Island 02865, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • FutureSearch Clinical Trials LP
    Austin, Texas 78756, United States
  • FutureSearch Clinical Trials, LP
    Dallas, Texas 75231, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • Department of Psychiatry, University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • Centre Hospitalier Spécialisé (CHS) du Jura - Centre Médico Psychiatrique (CMP)
    Dole, 39100, France
  • Hôpital Chalucet, Centre hospitalier intercommunal de Toulon la Seyne sur mer (CHITS)
    Toulon, 83000, France
  • Dipartimento Salute Mentale ASL 1
    Massa, 54100, Italy
  • A.O.U. Santa Chiara, U.O di Psichiatria 1 building n.4
    Pisa, 56100, Italy
  • Regional Government Institution (RGI) 'Lipetsk Regional Psychoneurology Hospital'
    Lipetsk, 398007, Russian Federation
  • Limited Liability Company (LLC) 'Research Center For Treatment and rehabilitation 'Phoenix'
    Rostov-on-Don, 344000, Russian Federation
  • St. Petersburg State Healthcare Institution (SPbSHI) "City Psychiatric Hospital #6"
    St. Peterburg, 191167, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution 'City Psychoneurology Dispensary #7 (with In-Patient Department)', (SPb SBHI "CPNDD-7")
    St. Petersburg, 190005, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution 'City Psychoneurology Dispensary #7 (with In-Patient Department)', (SPb SBHI "CPNDD-7"), at Daycare Facility #1
    St. Petersburg, 19005, Russian Federation
  • St. Petersburg State Government Healthcare Institution "City Psychiatric Hospital #4" (St. Petersburg Insane Asylum Distributor)
    St. Petersburg, 191119, Russian Federation
  • Military Medical Academy, Clnic for Psychiatry
    Belgrade, 11000, Serbia
  • Institute of Mental Health
    Dusica, 11000, Serbia
  • Clinical Centre Kragujevac, Clinic for psychiatry
    Kragujevac, 34000, Serbia
  • Clinical Centre Nis, Clinic for mental health protection
    Nis, 18000, Serbia
  • Specialized hospital for psychiatric diseases "Sveti Vracevi"
    Novi Knezevac, 23330, Serbia
  • Clinical Centre Vojvodine, Clinic for Psychiatry
    Novi Sad, 21000, Serbia
  • Nemocnica s poliklinikou v Prievidzi so sidlom v Bojniciach, Psychiatricke oddelenie
    Bojnice, 972 01, Slovakia
  • Psychiatricka ambulancia Mentum s.r.o.
    Bratislava, 82007, Slovakia
  • Psychiatricka nemocnica Michalovce n.o.
    Michalovce, 071 01, Slovakia
  • PsychoLine s.r.o. Psychiatricka ambulancia
    Rimavska Sobota, 97901, Slovakia
  • Nemocnica s poliklinikou sv Barbory Roznava a.s. Psychiatricke oddelenie
    Roznava, 048 01, Slovakia
  • "Centrum zdravia R.B.K., spol. s.r.o.
    Svidnik, 089 01, Slovakia
  • Cape Trial Centre
    Tygervalley, Western Cape 7530, South Africa
  • Research Unit, Department of Psychiatry Free State Psychiatric Complex
    Bloemfontein, 9300, South Africa
  • Denmar Hospital Consulting Rooms
    Pretoria, 0081, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2012
First posted
Mar 29, 2012
Start
Apr 2012
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Nov 20, 2014
Last update
Apr 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01566162
Responsible party
Sponsor
First posted
Mar 29, 2012
Start date
Apr 2012
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Nov 20, 2014
Last update
Apr 9, 2019

Study contacts

Lurasidone Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion